CTI Plans Label Expansion For Zevalin After Acquiring The NHL Drug From Biogen
This article was originally published in The Pink Sheet Daily
Executive Summary
Cell Therapeutics intends to initiate clinical studies to expand use of the drug into front-line lymphoma settings.